跳转至内容
Merck
CN
  • Irinotecan and temozolomide for treatment of neuroblastoma in a patient with renal failure on hemodialysis.

Irinotecan and temozolomide for treatment of neuroblastoma in a patient with renal failure on hemodialysis.

Pediatric blood & cancer (2013-11-26)
Amy E Armstrong, Jamie Dargart, Jennifer Reichek, David O Walterhouse, Debora Matossian, Richard A Cohn, Yasmin Gosiengfiao
摘要

Renal failure is a rare complication of neuroblastoma or its therapy. To our knowledge, no reports describe treatment of children with neuroblastoma with chemotherapy in the setting of renal failure and maintenance hemodialysis. We report a 6-year-old child with high-risk neuroblastoma who developed renal failure requiring long-term hemodialysis. She was subsequently treated with 13 cycles of intravenous irinotecan 20 mg/m(2)/day and oral temozolomide 100 mg/m(2)/day for 5 days before disease progression without any dose adjustments, transfusions, febrile neutropenia or diarrhea. This case demonstrates that irinotecan and temozolomide can be safely administered in children with renal failure requiring hemodialysis.

材料
Product Number
品牌
产品描述

Sigma-Aldrich
替莫唑胺, ≥98% (HPLC)
Sigma-Aldrich
伊立替康 盐酸盐, topoisomerase inhibitor
Supelco
替莫唑胺, VETRANAL®, analytical standard